Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer.

Abstract

This regimen of gemcitabine and cisplatin was effective, with high response and survival rates and few dosage modifications during its administration. Prospective randomized studies with other cisplatin-based combination chemotherapy regimens are indicated.

Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer

“…In phase II studies, 26 -54% stage IIIB/IV NSCLC patients responded to GC treatment. Good median and 1-year survival have been consistently observed (Abratt et al, 1997;Crino et al, 1997;Einhorn, 1997;Shepherd et al, 1997). Three randomized phase III studies demonstrated the superiority of GC over other chemotherapy regimens (Cardenal et al, 1999;Crino et al, 1999;Sandler et al, 2000).…”

“…It is likely that GC as an induction treatment may further improve survival in LAD-NSCLC patients. Abratt et al (1997) used GC in stage IIIB/IV patients delivering cisplatin on day 15 resulted in good response rate (52%), median survival (13 months) associated with low haematological toxicity and very few dose modifications of either gemcitabine or cisplatin. This schedule seems to be feasible for induction treatment.…”

“…This schedule seems to be feasible for induction treatment. Based on these observations, we designed a combined modality approach to LAD-NSCLC patients, using the GC regimen with a day 15 cisplatin schedule as was used in the Abratt et al (1997) study as induction chemotherapy.…”

Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer

“…10 -12 When combined with cisplatin and/or paclitaxel or vinorelbine, gemcitabine therapy shows an objective response rates in 28 -54% and the median survival durations ranged from 38 to 61.5 weeks. [13][14][15][16][17][18] However, the treatment of advanced lung cancer still remains a challenge to medical oncologists.Because of differences in mechanisms of action and toxicity profiles, the combination of the above 2 agents may have clinical potential. The present study was designed to determine whether gemcitabine potentiates the antitumor activity of VSV in vitro using both A549 (human lung adenocarcinoma) and LLC (murine Lewis lung carcinoma) cell lines and in vivo using A549 lung cancer xenografts and the murine syngeneic Lewis lung cancer, and if so, to examine the possible mechanism in the phenomenon, as well as to provide some potential implications for the treatment of human lung cancer.…”

“…10 -12 When combined with cisplatin and/or paclitaxel or vinorelbine, gemcitabine therapy shows an objective response rates in 28 -54% and the median survival durations ranged from 38 to 61.5 weeks. [13][14][15][16][17][18] However, the treatment of advanced lung cancer still remains a challenge to medical oncologists.…”